Keyi Pharma's Dual-Target CAR-T Therapy KQ-2003 Secures Over $2.1 Billion Global Licensing Deal with ERIGEN LLC

Jul 22, 2025 16:47 CST Updated 16:47

Novatim

Innovative Drug Developer for Tumor Immunotherapy

On July 22, 2025, Novatim Immune Therapeutics (Zhejiang) Co., Ltd. ("Novatim") announced a collaboration with a U.S.-based biopharmaceutical company.ERIGEN LLCReached a strategic cooperation, both parties signed an agreement on Novatim's independently developed world's first parallel-enhanced dual-target CAR-T cell therapy product.Exclusive Overseas Licensing Agreement for KQ-2003 (Targeting BCMA/CD19)This collaboration covers global rights outside Greater China (excluding India, Turkey, and Russia), and ERIGEN will obtain exclusive development, registration, and commercialization rights for the product in the relevant regions.

In addition, the agreement also grants ERIGEN the use of KQ-2003's key patented structure and sequence forThe Rights to Develop "Universal CAR-T Cell Therapy"According to the agreement, Novatim retains full rights to this universal product in the Greater China region, laying the foundation for subsequent co-development and regional commercialization.

According to the terms of the cooperation, Novatim will obtain$15 millionRecent development milestone payments, with eligibility for a total amount up to$1.32 billionmilestone payments during the R&D, registration, and commercialization phases. In addition, Novatim will also receive a maximum amount based on the net sales of KQ-2003 in the licensed territory.$800 millionSales split.

Significance of Cooperation: Accelerating Global Layout

KQ-2003 is currently undergoing Phase Ib clinical trials in China. This collaboration marks a crucial step in the internationalization of Novatim's innovative pipeline, bringing new hope for treatment to patients with relapsed/refractory multiple myeloma (rrMM) and POEMS syndrome worldwide.

Chairman and General Manager of NovatimWu GuoxiangPh.D.Indicates:

“KQ-2003 is the benchmark product of Novatim's CAR-T platform. Its differentiated structural design effectively addresses the challenges of recurrence in hematological tumor treatment and suboptimal efficacy in certain indications. This collaboration recognizes Novatim's technological innovation and clinical value, and we will work together.ERIGEN LLCTo provide accessible and affordable cell therapies for patients worldwide.”

ERIGEN LLCChief Executive OfficerMatt AngelDr. stated:

“KQ-2003In existing clinical trials, it has demonstrated highly promising efficacy signals. Its parallel dual-target structure design offers significant advantages in overcoming recurrence risks and efficacy variations, providing a new option for traditional approaches.CAR-TThe unmet areas of treatment are effectively supplemented. Relying on ourIn general-purposeCAR-TYears of accumulation in development and industrial operation, andStrategic Support from Numerous Top International Investment Institutions, we will accelerate the advancementKQ-2003Multicenter clinical trials outside of Greater China, simultaneously launching the next-generation universal typeCAR-TThe clinical development of the product aims to provide more accessible and innovative cell therapy options for patients with cancer and autoimmune diseases worldwide.

About KQ-2003

KQ-2003 is an innovative therapy developed by Novatim based on its enhanced dual-target CAR-T platform. Through a parallel structural design and optimization of the signaling domain, it significantly enhances the persistence and anti-tumor activity of CAR-T cells while reducing the risk of recurrence associated with traditional CAR-T therapies. Its core advantages include: excellent efficacy, safety benefits, and cost competitiveness. Currently inRelapsed/Refractory Multiple Myeloma (rrMM) and POEMS SyndromeThe registrational clinical trials have achieved exciting efficacy.

About Novatim

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.Founded in 2018, Novatim Immune Therapeutics (Zhejiang) Co., Ltd. is a biopharmaceutical technology enterprise focusing on the research and development of innovative drugs for cancer immunotherapy and their clinical applications. Based on clinical needs and differentiation, it is committed to efficient and groundbreaking R&D innovation, with a layout across three major R&D platforms:Bifunctional Antibody Platform, Nano Bispecific ADC Platform, Enhanced Dual-Target CAR-T PlatformIndependently developed from scratch more than 10 novel, differentiated potential FIC/BIC pipelines.

Based on the bispecific antibody platform, independently developed by the companyChina's First βγ-Biased PD1/IL2 Fusion ProteinCurrently, the single drug is in Phase Ⅰb clinical trials in China, and has also received IND approval in the United States; based on the nano bispecific ADC platform, independently developed by the company.World's First Nano Bispecific ADCCurrently, the single drug is in Phase Ⅰa clinical trials in China and has received IND approval in the United States. Based on the enhanced dual-target CAR-T platform, the company has independently developed the world's first parallel-enhanced structure dual-target CAR-T, which is currently in Phase Ⅰ/Ⅱa clinical trials.

AboutERIGEN LLC

ERIGEN LLCFactor Bioscience's Affiliated Companies, this time as a partner undertaking the development and commercialization responsibilities of KQ-2003 in markets outside Greater China. Factor Bioscience is a company focused onA Global Innovative Biotechnology Company in the Field of Gene Editing and Cell Therapy, the core technology is its independently developedmRNA Cell Programming Platform，The platform integratesNon-viral CRISPR Delivery, Cell Reprogramming, and mRNA Expression RegulationThree major capabilities, featuring high scalability and tissue specificity.

Relying on this platform, Factor has establishedStand UpMore than ten differentiated pipelines covering major diseases such as genetic disorders and cancer, among which multiple pipelines have entered the IND-enabling or clinical stage.Non-viralCRISPR/mRNA Delivery SystemIn a global leading position in technology, has obtained multiple international patent authorizations. Factor is committed toProgrammable Gene and Cell Therapy TechnologyAs a breakthrough, providing innovative solutions for significant unmet medical needs in the field of major diseases.

E.N.D

Previous article recommendations:(Click on the article title below to open the original text)

An Exosome Company in China Officially Opens for Production

Delivery Efficiency Increased by 1500 Times! New Delivery Technology Greatly Enhances Targeting of RNA Drugs

Nearly 100 Million! Sales Performance of the First Mesenchymal Stem Cell Therapy in the U.S. Announced, Company's Stock Price Soars

An Exosome Company in China Officially Starts Operations

Nearly $40 Million! A Cell Therapy Company in China Completes Series B Financing

Grand Opening! Qinhuangdao First Bio-Stem Cell Technology Company Junzhen Hospital Boosts High-Quality Development of the Life and Health Industry

Stock Price Surges Over 700%! Breakthrough Progress in a Cell Therapy Product

World's First! Bayer Subsidiary Completes First Patient Dosing in iPS Cell Therapy for Primary Photoreceptor Disease

FDA Rejects World's First Exosome Cell Therapy

6 Hours to Complete CAR-T Preparation, No Chemotherapy Conditioning, 100% Remission with No Severe Side Effects: The World’s First Triple-Target Hematologic Tumor CAR-T Cell Drug Achieves Milestone Results

Combining Optogenetics and iPSCs, Chinese Team Develops Light-Controlled "Smart" Stem Cell Vaccine for the Prevention of Various Immunogenic Tumors

Stock Price Surges 515%, A Cell Therapy Company's Core Pipeline Shines with Impressive Clinical Data

Breakthrough in AAV Vector Bottleneck: Another Latest Groundbreaking Achievement in Gene Therapy Published in China

Nearly 100 Million! A Cell Therapy Company in China Completes New Round of Financing

CDE of NMPA Releases "Technical Guiding Principles for Research and Evaluation of Pharmaceutical Changes in Cell Therapy Products (Draft for Comments)"

Breakthrough in iPS Cell Technology: Production Costs Reduced by Over 90%, Production Cycle Shortened to 3 Weeks

China's First CGT R&D and Production Center Officially Launched

China Approves Clinical Trial for World's First Cell Therapy Product for Chronic Hepatitis B

SoundBright: CapitalMaterialComeSource: Official Company，This article aims toKnowledge Sharing, all content is for reference only and does not constitute any advice.。